Cargando…

Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma

In this study, we aimed to evaluate the efficacy of PD-1 inhibitors in combination with concurrent CRT/CT for patients with inoperable ESCC in the real world and to find predictors for the efficacy of PD-1 inhibitors. Patients with unresectable ESCC were evaluated at baseline. The clinical data of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Tianhui, Ti, Wenqi, Song, Qingxu, Cheng, Yufeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139405/
https://www.ncbi.nlm.nih.gov/pubmed/35621628
http://dx.doi.org/10.3390/curroncol29050238
_version_ 1784714852201136128
author Wei, Tianhui
Ti, Wenqi
Song, Qingxu
Cheng, Yufeng
author_facet Wei, Tianhui
Ti, Wenqi
Song, Qingxu
Cheng, Yufeng
author_sort Wei, Tianhui
collection PubMed
description In this study, we aimed to evaluate the efficacy of PD-1 inhibitors in combination with concurrent CRT/CT for patients with inoperable ESCC in the real world and to find predictors for the efficacy of PD-1 inhibitors. Patients with unresectable ESCC were evaluated at baseline. The clinical data of patients with ESCC who received CRT/CT with or without PD-1 inhibitor were collected and retrospectively reviewed. The objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) were analyzed statistically. A total of 96 patients with ESCC were included. As compared with a control group (n = 48), the PFS (6.0 months vs. 5.0 months, p = 0.025) and 6-month OS (70.8% vs. 47.9%, p < 0.001) were significantly longer in the ICIs group (n = 48). There were no significant differences in ORR and 12-month OS between the two groups. In addition, we found that body mass index (BMI) was associated with PFS (HR 0.85, 95% CI 0.76–0.95, and p = 0.004) and OS (HR 0.82, 95% CI 0.69–0.98, and p = 0.033) in the ICIs group. PD-1 inhibitors combined with CRT/CT is safe with acceptable complications and improved survival for patients with inoperable ESCC. CRT plus PD-1 inhibitor has superior antitumor efficacy. BMI was positively correlated with the efficacy of PD-1 inhibitors.
format Online
Article
Text
id pubmed-9139405
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91394052022-05-28 Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma Wei, Tianhui Ti, Wenqi Song, Qingxu Cheng, Yufeng Curr Oncol Article In this study, we aimed to evaluate the efficacy of PD-1 inhibitors in combination with concurrent CRT/CT for patients with inoperable ESCC in the real world and to find predictors for the efficacy of PD-1 inhibitors. Patients with unresectable ESCC were evaluated at baseline. The clinical data of patients with ESCC who received CRT/CT with or without PD-1 inhibitor were collected and retrospectively reviewed. The objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) were analyzed statistically. A total of 96 patients with ESCC were included. As compared with a control group (n = 48), the PFS (6.0 months vs. 5.0 months, p = 0.025) and 6-month OS (70.8% vs. 47.9%, p < 0.001) were significantly longer in the ICIs group (n = 48). There were no significant differences in ORR and 12-month OS between the two groups. In addition, we found that body mass index (BMI) was associated with PFS (HR 0.85, 95% CI 0.76–0.95, and p = 0.004) and OS (HR 0.82, 95% CI 0.69–0.98, and p = 0.033) in the ICIs group. PD-1 inhibitors combined with CRT/CT is safe with acceptable complications and improved survival for patients with inoperable ESCC. CRT plus PD-1 inhibitor has superior antitumor efficacy. BMI was positively correlated with the efficacy of PD-1 inhibitors. MDPI 2022-04-20 /pmc/articles/PMC9139405/ /pubmed/35621628 http://dx.doi.org/10.3390/curroncol29050238 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wei, Tianhui
Ti, Wenqi
Song, Qingxu
Cheng, Yufeng
Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma
title Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma
title_full Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma
title_fullStr Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma
title_full_unstemmed Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma
title_short Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma
title_sort study of pd-1 inhibitors in combination with chemoradiotherapy/chemotherapy in patients with esophageal squamous carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139405/
https://www.ncbi.nlm.nih.gov/pubmed/35621628
http://dx.doi.org/10.3390/curroncol29050238
work_keys_str_mv AT weitianhui studyofpd1inhibitorsincombinationwithchemoradiotherapychemotherapyinpatientswithesophagealsquamouscarcinoma
AT tiwenqi studyofpd1inhibitorsincombinationwithchemoradiotherapychemotherapyinpatientswithesophagealsquamouscarcinoma
AT songqingxu studyofpd1inhibitorsincombinationwithchemoradiotherapychemotherapyinpatientswithesophagealsquamouscarcinoma
AT chengyufeng studyofpd1inhibitorsincombinationwithchemoradiotherapychemotherapyinpatientswithesophagealsquamouscarcinoma